R&D Towards better quality of life, GNT Pharma

Clinical Research

AWAKEAntioxidant and NMDA receptor blocker Weans Anoxic brain damage of KorEa OHCA patients

  • Phase II clinical study in Korea to examine the safety and efficacy of nelonemdaz in 150 patients resuscitated after out-of-hospital cardiac arrest, with restoration of spontaneous circulation achieved within 4 hours post arrest.
  • Participating Hospitals (Department of Emergency Medicine): 5 hospitals including Samsung Medical Center
  • Designated by the Ministry of Food and Drug Safety in December 2019 as an orphan drug under development for cardiac arrest patients who are given artificial resuscitation.
  • Selected by the Ministry of Health and Welfare in 2020 as a new drug development project for rare disease and supported for research funding.
Total No. of
Enrolled Patients
Progress RateAs of December 1, 2022
98 Pts. 65.3%
Target No. of Patients 150 Pts.